Fennec Pharmaceuticals Inc (NASDAQ:FENC) Director Rosty Raykov Sells 10,000 Shares of Stock

Fennec Pharmaceuticals Inc (NASDAQ:FENC) Director Rosty Raykov sold 10,000 shares of Fennec Pharmaceuticals stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $6.08, for a total transaction of $60,800.00. Following the transaction, the director now directly owns 83,863 shares in the company, valued at approximately $509,887.04. This trade represents a 10.65 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Rosty Raykov also recently made the following trade(s):

• On Thursday, December 5th, Rosty Raykov sold 796 shares of Fennec Pharmaceuticals stock. The shares were sold at an average price of $6.04, for a total transaction of $4,807.84.
• On Monday, November 4th, Rosty Raykov sold 2,431 shares of Fennec Pharmaceuticals stock. The stock was sold at an average price of $4.31, for a total transaction of $10,477.61.

Fennec Pharmaceuticals Stock Performance

Shares of FENC stock opened at $6.10 on Wednesday. The company has a debt-to-equity ratio of 9.86, a current ratio of 7.80 and a quick ratio of 7.64. The company’s fifty day moving average price is $5.51 and its two-hundred day moving average price is $5.52. The firm has a market capitalization of $167.57 million, a P/E ratio of -60.99 and a beta of 0.34. Fennec Pharmaceuticals Inc has a 12 month low of $3.96 and a 12 month high of $11.49.

Wall Street Analyst Weigh In

A number of research analysts have commented on FENC shares. HC Wainwright restated a “buy” rating and set a $13.00 price objective on shares of Fennec Pharmaceuticals in a research note on Tuesday, December 17th. Stephens raised Fennec Pharmaceuticals to a “strong-buy” rating in a research report on Monday, November 18th. Finally, Wedbush restated an “outperform” rating and issued a $13.00 price target on shares of Fennec Pharmaceuticals in a report on Friday, December 20th.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the business. State Street Corp increased its holdings in Fennec Pharmaceuticals by 2.2% during the 3rd quarter. State Street Corp now owns 328,259 shares of the company’s stock worth $1,641,000 after purchasing an additional 7,053 shares during the last quarter. Bank of New York Mellon Corp grew its position in shares of Fennec Pharmaceuticals by 42.8% during the second quarter. Bank of New York Mellon Corp now owns 68,724 shares of the company’s stock worth $420,000 after buying an additional 20,602 shares in the last quarter. WINTON GROUP Ltd bought a new stake in shares of Fennec Pharmaceuticals in the second quarter worth $409,000. Advantage Alpha Capital Partners LP acquired a new stake in Fennec Pharmaceuticals in the third quarter valued at $264,000. Finally, Barclays PLC boosted its stake in Fennec Pharmaceuticals by 274.3% during the 3rd quarter. Barclays PLC now owns 31,319 shares of the company’s stock valued at $157,000 after acquiring an additional 22,951 shares during the last quarter. Institutional investors and hedge funds own 55.51% of the company’s stock.

Fennec Pharmaceuticals Company Profile

Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children.